A novel design using a virtual control group to evaluate non-inferiority of nevirapine and lamivudine dual maintenance in HIV therapy. | ClinicLens

Reducing the number of drugs in combined antiretroviral therapy (cART) likely reduces toxicity. We hypothesized that dual therapy (DT) with nevirapine (NVP) and lamivudine (3TC) would be non-inferior to a virtual control without treatment failure. This multicenter study enrolled

Medical Literature · Updated 2026-08-07

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.